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Background
Epidermal Growth Factor Receptor-2 (HER-2) and
Estrogen receptor-alpha (ER-a) have been found to be
dysregulated in several types of cancer. Their dysregula-
tion is associated with aberrant epigenetic modifications.
Additionally, expression of ER-a and HER-2 is inversely
correlated; their crosstalk has been shown to be involved
in endocrine therapy resistance mechanisms [1]. Thera-
pies targeting either receptor result in cell proliferation
inhibition for some cancer types; the anti-cancer effect
might be further optimized to be more efficient and
applicable for more cancer types by co-targeting the
genes at the DNA level. As epigenetic modifications pro-
vide a way to modify expression of genes in a sustained
manner we aim to downregulate HER-2 and ER-a by
inducing epigenetic silencing marks specifically onto
their promoters (Epigenetic Editing [2]). We also aim to
discover the possible crosstalk of ER-a with HER-2 and
other important genes in cancer.
Methods and materials
Towards downregulation of HER-2 and ER-a, expression
and epigenetic modification status of promoter of these
genes were assessed in a panel of cancer cell lines (bisulfite
sequencing and ChIP). Designed zinc finger proteins
(ZFPs) targeting genes promoters were fused to a tran-
scription repressor domain [SKD, histone methyltrans-
ferases (G9a, SUV39H1), or a DNA methyltransferase
domain (C141S [3])] and expressed in cancer cells through
viral transduction.
Results
HER2-ZFP fused to G9a or SUV39H1 induced the
intended silencing histone methylation marks (H3K9me2,
H3K9me3) on the HER-2 promoter. Up to 4-fold induced
H3K9me2 mark was associated with up to 54 ± 2.9%
downregulation of HER-2 expression (P<0.0001). Of note,
downregulation of HER-2 by induced H3K9 methylation
mark was associated with inhibition of cell proliferation
and clonogenicity. Additionally, up to 50% downregulation
of ER-a was obtained by a ZFP specif c to ER-a fused to
SKD, G9a, and C141S.
Conclusions
These results show that targeted induction of epigenetic
marks is instructive in downregulation of HER-2 and ER-
a expression. We conclude that Epigenetic Editing might
provide a novel and synergistic approach to modulate
(onco)genes. In addition, investigation of ER-a crosstalk
with HER-2 and other genes might be promising to better
interfere with pathways involved in cancer.
Author details
1Epigenetic Editing, Dept. Medical Biology and Pathology, 9713 GZ
Groningen, The Netherlands. 2Dept. Medical Oncology, 9713 GZ Groningen,
The Netherlands.
Published: 18 March 2013
References
1. Arpino G, Wiechmann L, Osborne CK, Schif R: Crosstalk between the
estrogen receptor and the HER tyrosine kinase receptor family:
molecular mechanism and clinical implications for endocrine therapy
resistance. Endocr Rev 2008, 29(2):217-233.
2. de Groote ML, Verschure PJ, Rots MG: Epigenetic editing: Targeted
rewriting of epigenetic marks to Modulate Expression of selected target
genes. Nucleic Acids Res 2012, 40(21):10596-10613.
3. van der Gun BT, Maluszynska-Hofman M, Kiss A, Arendzen AJ, Ruiters MH,
McLaughlin PM, Weinhold E, Rots MG: Targeted DNA methylation by a
1Epigenetic Editing, Dept. Medical Biology and Pathology, 9713 GZ
Groningen, The Netherlands
Full list of author information is available at the end of the article
Falahi et al. Epigenetics & Chromatin 2013, 6(Suppl 1):P15
http://www.epigeneticsandchromatin.com/content/6/S1/P15
© 2013 Falahi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
DNA methyltransferase coupled to a triple helix forming oligonucleotide
to down-regulate the epithelial cell adhesion molecule. Bioconjug Chem
2010, 21(7):1239-1245.
doi:10.1186/1756-8935-6-S1-P15
Cite this article as: Falahi et al.: Gene specific overwriting of epigenetic
signatures to modulate the expression of selected tumor-promoting
genes in cancer. Epigenetics & Chromatin 2013 6(Suppl 1):P15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Falahi et al. Epigenetics & Chromatin 2013, 6(Suppl 1):P15
http://www.epigeneticsandchromatin.com/content/6/S1/P15
Page 2 of 2
